These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35813116)

  • 21. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway.
    Paumelle R; Tulasne D; Kherrouche Z; Plaza S; Leroy C; Reveneau S; Vandenbunder B; Fafeur V
    Oncogene; 2002 Apr; 21(15):2309-19. PubMed ID: 11948414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
    Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
    Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway.
    Zhang X; Liu G; Ding L; Jiang T; Shao S; Gao Y; Lu Y
    J Cell Biochem; 2018 Mar; 119(3):2864-2874. PubMed ID: 29073728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras/Raf-independent mechanism.
    Romerio F; Riva A; Zella D
    Br J Cancer; 2000 Aug; 83(4):532-8. PubMed ID: 10945503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
    Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway.
    Woods D; Cherwinski H; Venetsanakos E; Bhat A; Gysin S; Humbert M; Bray PF; Saylor VL; McMahon M
    Mol Cell Biol; 2001 May; 21(9):3192-205. PubMed ID: 11287623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
    Ghanm SE; Shebl NA; El Sayed IET; Abdel-Bary HM; Saad BF; Othman Saad W
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3203-3210. PubMed ID: 34710996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
    Shilo A; Ben Hur V; Denichenko P; Stein I; Pikarsky E; Rauch J; Kolch W; Zender L; Karni R
    RNA; 2014 Apr; 20(4):505-15. PubMed ID: 24572810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of extracellular signal-regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes.
    Minagawa T; Yamazaki K; Masugi Y; Tsujikawa H; Ojima H; Hibi T; Abe Y; Yagi H; Kitago M; Shinoda M; Itano O; Kitagawa Y; Sakamoto M
    Hepatol Res; 2020 Mar; 50(3):353-364. PubMed ID: 31702093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Mun EJ; Green P; Berry K; Ioannou GN
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):47-52. PubMed ID: 30142097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells.
    Liu P; Wilson MJ
    J Cell Physiol; 2012 Feb; 227(2):867-76. PubMed ID: 21898400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.
    Zhang Q; Gong R; Qu J; Zhou Y; Liu W; Chen M; Liu Y; Zhu Y; Wu J
    J Virol; 2012 Feb; 86(3):1544-54. PubMed ID: 22114332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opposing roles of Ras/Raf oncogenes and the MEK1/ERK signaling module in regulation of expression and adhesive function of surface transglutaminase.
    Akimov SS; Belkin AM
    J Biol Chem; 2003 Sep; 278(37):35609-19. PubMed ID: 12832399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma.
    Schuierer MM; Bataille F; Weiss TS; Hellerbrand C; Bosserhoff AK
    Oncol Rep; 2006 Sep; 16(3):451-6. PubMed ID: 16865242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A ΔRaf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures.
    He S; Krens SG; Zhan H; Gong Z; Hogendoorn PC; Spaink HP; Snaar-Jagalska BE
    J Pathol; 2011 Sep; 225(1):19-28. PubMed ID: 21744342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.
    Park JI; Strock CJ; Ball DW; Nelkin BD
    Mol Cell Biol; 2003 Jan; 23(2):543-54. PubMed ID: 12509453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
    Chen Y; Liu YC; Sung YC; Ramjiawan RR; Lin TT; Chang CC; Jeng KS; Chang CF; Liu CH; Gao DY; Hsu FF; Duyverman AM; Kitahara S; Huang P; Dima S; Popescu I; Flaherty KT; Zhu AX; Bardeesy N; Jain RK; Benes CH; Duda DG
    Sci Rep; 2017 Mar; 7():44123. PubMed ID: 28276530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.